Gilead Sciences received FDA approval for its long-acting injectable HIV pre-exposure prophylaxis drug, lenacapavir (Yeztugo), marking a major step forward in preventing HIV infection. Administered twice annually, it offers a compelling alternative to daily oral pills, addressing adherence challenges. Phase 3 trials demonstrated remarkable efficacy, including 100% prevention in cisgender women and 99.9% in broader populations, outperforming established PrEP regimens like Truvada. This approval is particularly timely as the U.S. faces a persistent HIV epidemic and aims to expand protective options to at-risk populations with improved convenience and compliance features.